ARCA biopharma, Inc., a biopharma company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, has submitted an Investigational New Drug application with the U.S. FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of hospitalized patients with COVID-19. ARCA anticipates initiating the Phase IIb portion of a sequential Phase IIb/III clinical evaluation of AB201 as early as 4Q20. AB201 ...